Nuvig Therapeutics is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics to reduce autoimmune dysregulation without broad immunosuppression. Its lead candidate, NVG-2089, is a first-in-class recombinant Fc fragment engineered to bind type II Fc receptors and engage an endogenous regulatory mechanism that improves autoimmune dysregulation. Phase 1 single ascending dose and multiple ascending dose studies of NVG-2089 have been completed and showed safety, tolerability, dose-proportional pharmacokinetics, and pharmacodynamic evidence of target engagement. The company is advancing NVG-2089 into Phase 2 development in chronic inflammatory demyelinating polyneuropathy (CIDP) and other undisclosed indications with high unmet need. Proceeds from the Series B financing will support clinical proof-of-concept studies for NVG-2089 and advance Nuvig's preclinical pipeline. Nuvig is based in Menlo Park, California. Nuvig is developing genetically engineered protein therapeutics that activate immune-regulatory receptors to re-establish immune homeostasis following inflammation. The company is building a pipeline of differentiated protein candidates designed to target affected tissues in a disease-specific manner. Nuvig’s approach aims to rebalance immune function rather than rely on traditional immune suppression, with a lead molecule the company believes could offer a differentiated safety and efficacy profile. Management states initial preclinical data support broad activity across a variety of autoimmune diseases. The company plans a clinical development strategy to quickly obtain proof-of-concept in patients, followed by indication expansion and further pipeline growth. To support these plans, Nuvig has secured external financing to advance its programs toward the clinic.

Total raised

$208M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2024